Strong Customer Gains and Standout US Growth Helps Entersekt Solidify Market Position
16.8.2023 12:00:00 EEST | Business Wire | Press release
Entersekt, a global leader in transaction authentication solutions for financial fraud prevention, today announced strong growth in both revenue and number of customers, fueled by continued US expansion and strategic partnerships. Since the investment by Accel-KKR in fiscal 2022, Entersekt has seen its business outside of South Africa accelerate rapidly with contracted annual recurring revenue increase by 191%, and nearly 220% growth in US-based customers in fiscal 2023 alone.
“Our solid growth in a difficult global business climate is testament to Entersekt’s innovation and expertise addressing emerging fraud threats,” said Schalk Nolte, Entersekt CEO. “Our reputation of delivering the highest level of security to financial institutions across all digital channels without compromising user experience is capturing the attention of decision makers – many of whom now recognize the urgent need to adopt more robust authentication methods to replace the traditional approaches that are proving to be vulnerable to increasingly sophisticated fraud attempts.”
“We are particularly pleased with our performance in the US which is nearing hypergrowth. The region remains a key focus for the year ahead and we have identified key partners and talent who are well known in the industry to help us to accelerate the current trajectory. The market has shown itself eager to adopt our technology which has a proven track record with financial institutions around the world,” Nolte explained.
“As fraud and financial crime continues to threaten financial institutions around the world, the opportunity for innovative technology firms to help mitigate these risks is greater than ever,” said Julie Conroy, Head of Risk Insights at Datos Insights. “Entersekt’s steady growth and expansion is a key indicator of the appetite for FIs of all sizes to seek solutions that can reduce fraud while ensuring an optimal user experience.”
Fiscal 2023 Performance Highlights
Market-leading fraud prevention Innovations
The Entersekt team continued to innovate well ahead of the industry curve, with three new patents granted in FY2023, adding to the more than 60 existing technology patents. These include Context Aware™ Authentication which is the first cross-channel fraud prevention to consider the originating channel, the transaction context, the analysis and orchestration of both active and silent risk signals, the available authentication mechanisms, as well as the customer’s choice to determine the most appropriate authentication journey - all in real-time.
“Many banks continue to struggle with siloed authentication mechanisms, with different solutions for online banking, in-branch offerings, call centers, digital payments and open banking, with each using its own authentication technology. We're providing the ability to break down all those silos and have one common authentication platform across all the various channels. Not only does this provide a much better user and customer experience, but also helps orchestrate all that data to help banks make better decisions,” Nolte said.
New strategic channel and technology partnerships
The Entersekt team continued to solidify new partnerships in all regions, improving it’s go-to-market scale and creating new market opportunities. By supporting pre-integration, these partnerships enabled banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform, adding biometric authentication capabilities to the Q2 online and mobile banking applications.
Expanded senior management
To support the significant growth and opportunity in the US market, Entersekt made ten new director, VP or C-level hires in the US in FY23. Its executive team and company headquarters is now based both in the US and South Africa, showcasing the importance of and commitment to regional representation.
Three new C-level appointments, all with decades of leadership experience, include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.
- Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank, Cardinal Commerce and Mastercard.
- Sampath has led new product initiatives for over 20 years, scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
- Moreno’s experience includes senior marketing leadership roles spanning over 20 years with tech companies such as Bottomline and Datawatch.
More growth on the horizon
Looking ahead, Nolte said the industry must prepare for the continued challenges of account takeover fraud schemes and authorized push payment fraud, saying the rise of real-time payments, particularly through mobile apps, has introduced a need for faster and more effective fraud detection mechanisms.
“Our vision for the future is centered around becoming a leading force in the digital landscape, revolutionizing the way people conduct secure transactions on digital platforms. With the backing of our US-based investors, key partners and a customer-centric approach, we are poised for exceptional success in the year ahead and beyond,” Nolte said.
About Entersekt
Entersekt ensures that digital financial transactions are secure and free from unnecessary friction. The company provides a single cross-channel platform for financial services institutions to meet authentication requirements and optimize user experiences. With a range of options available for deployment and configuration, Entersekt’s solutions are fully customizable across all channels and devices. A strong track record of over ten years’ working with leading financial services institutions across the United States, Europe, and Africa, combined with multiple patented security innovations, has established Entersekt as a global industry leader in authentication. Backed by companies like Silicon Valley-based Accel-KKR, one of the world’s top private equity firms, Entersekt continues to expand its footprint across key regions. For more information, visit entersekt.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230816112272/en/
Contact information
Frank Moreno
Chief Marketing Officer
frank@entersekt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
